dc.contributor.author | Ousler, George W. | en_US |
dc.contributor.author | Rimmer, David | en_US |
dc.contributor.author | Smith, Lisa M. | en_US |
dc.contributor.author | Abelson, Mark B. | en_US |
dc.date.accessioned | 2017-12-06T16:20:32Z | |
dc.date.issued | 2017 | en_US |
dc.identifier.citation | Ousler, George W., David Rimmer, Lisa M. Smith, and Mark B. Abelson. 2017. “Use of the Controlled Adverse Environment (CAE) in Clinical Research: A Review.” Ophthalmology and Therapy 6 (2): 263-276. doi:10.1007/s40123-017-0110-x. http://dx.doi.org/10.1007/s40123-017-0110-x. | en |
dc.identifier.issn | | en |
dc.identifier.uri | http://nrs.harvard.edu/urn-3:HUL.InstRepos:34493184 | |
dc.description.abstract | The many internal and external factors that contribute to the pathophysiology of dry eye disease (DED) create a difficult milieu for its study and complicate its clinical diagnosis and treatment. The controlled adverse environment (CAE®) model has been developed to minimize the variability that arises from exogenous factors and to exacerbate the signs and symptoms of DED by stressing the ocular surface in a safe, standardized, controlled, and reproducible manner. By integrating sensitive, specific, and clinically relevant endpoints, the CAE has proven to be a unique and adaptable model for both identifying study-specific patient populations with modifiable signs and symptoms, and for tailoring the evaluation of interventions in clinical research studies. | en |
dc.language.iso | en_US | en |
dc.publisher | Springer Healthcare | en |
dc.relation.isversionof | doi:10.1007/s40123-017-0110-x | en |
dc.relation.hasversion | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5693827/pdf/ | en |
dash.license | LAA | en_US |
dc.subject | Aqueous-deficient dry eye | en |
dc.subject | Clinical trials | en |
dc.subject | Controlled adverse environment | en |
dc.subject | Disease models | en |
dc.subject | Drug screening | en |
dc.subject | Dry eye disease | en |
dc.subject | Efficacy endpoints | en |
dc.subject | Evaporative dry eye | en |
dc.subject | Keratitis | en |
dc.subject | Ocular discomfort | en |
dc.subject | Tear film break up | en |
dc.subject | Tear film deficiency | en |
dc.title | Use of the Controlled Adverse Environment (CAE) in Clinical Research: A Review | en |
dc.type | Journal Article | en_US |
dc.description.version | Version of Record | en |
dc.relation.journal | Ophthalmology and Therapy | en |
dash.depositing.author | Abelson, Mark B. | en_US |
dc.date.available | 2017-12-06T16:20:32Z | |
dc.identifier.doi | 10.1007/s40123-017-0110-x | * |
dash.contributor.affiliated | Abelson, Mark | |